MARM yields 5.97% · MRK yields 3.25%● Live data
📍 MRK pulled ahead of the other in Year 8
Combined, MARM + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MARM + MRK for your $10,000?
The investment objective of the FT Vest U.S. Equity Max Buffer ETF - March (the "Fund") is to seek to provide investors with returns (before fees and expenses) that match the price return of the SPDR S&P 500 ETF (the "Underlying ETF") up to a predetermined upside cap while seeking to provide the maximum available buffer (before fees and expenses), against Underlying ETF losses over an approximate period of one year (the "Target Outcome Period"). Over the Target Outcome Period from March 24, 2025 through March 20, 2026, the Fund seeks to buffer against 100% of Underlying ETF losses and limit gains up to a predetermined upside cap of 7.18%. When the Fund's fees and expenses are taken into account, the cap is 6.33% and the buffer is 99.15%.
Full MARM Calculator →Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.